What Does a Kidney Mass in a Small Child Mean? Wilms Tumour
What Does a Kidney Mass in a Small Child Mean? Wilms Tumour

One word in the report matters more than the rest, and it is renal. A mass in a small child's abdomen can start in several different places, and where it started decides most of what follows: which operation, which drugs, which scans. When the mass sits inside the kidney with kidney tissue curved around it, the working diagnosis is usually Wilms tumour, and the honest thing to say early is that the outlook for most children treated for it is good, with nothing promised about your child in particular. The answer also arrives in fragments, and you are the one carrying the thread between them. Healz exists to carry it with you.
This page is deliberately not the other page. Neuroblastoma also shows up as a firm abdomen in a small child, and the two are told apart by origin, by age, by what the urine shows and by how the mass behaves around blood vessels.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
What does it mean that the mass is in the kidney and not beside it?
Wilms tumour, also called nephroblastoma, begins in the kidney itself, in cells left over from the way the kidney was built before birth. It is the most common kidney tumour of infancy and childhood, with roughly 650 new diagnoses a year in the United States. Per the NCI PDQ health professional summary, the mean age at diagnosis is 44 months for a tumour in one kidney and 31 months when both are involved.
Neuroblastoma starts somewhere else: in developing sympathetic nerve tissue, most often the adrenal gland that sits on top of the kidney. The NCI PDQ health professional summary on neuroblastoma gives a median age at diagnosis of 17 months. So the typical Wilms child is a toddler or a preschooler, and the typical neuroblastoma child is a baby. We wrote about that side of the fork separately, in an abdominal mass in an infant and its markers.
On the scan the difference is one of origin, not of size. A radiological review of neuroblastoma and nephroblastoma in Cancer Imaging describes the claw sign in Wilms tumour, a rim of normal kidney tissue cupped around the mass, showing it grew out of the kidney rather than beside it. In Wilms tumour the vessels are displaced rather than encased, though the tumour does grow into the renal vein or the vena cava in roughly 5 to 10 percent of cases; neuroblastoma encases them and can extend across the midline. Calcification is the other separator: on CT it shows in 80 to 90 percent of neuroblastomas and about 10 percent of Wilms tumours. MRI picks it up less reliably, so those figures belong to a CT report.
Then the urine. The PDQ summary on neuroblastoma says that diagnosis can rest on tumour cells in the bone marrow plus raised urinary catecholamine metabolites, VMA and HVA, without tissue from the tumour. Wilms tumour is not found that way, and urinary catecholamines are not part of its workup. But a normal catecholamine result does not on its own rule neuroblastoma out, and a neuroblastoma invading the kidney can mimic Wilms tumour. Tissue, after the operation, is what settles it. In an adult the same finding runs a different route, usually a kidney mass found by chance on a scan.
Why will nobody keep pressing on my child's belly?
Most children with Wilms tumour are not ill when it is found. The PDQ summary describes the usual presentation as a nontender, large flank mass noticed by a parent when the child is bathed or dressed, with abdominal pain in 40 percent of children and high blood pressure in about 25 percent at presentation.
Once the mass is on the radar, the hands come off. NCCN's Wilms tumour guideline warns clinicians to be gentle when feeling a mass in the kidney area, because a Wilms tumour can rupture if it is touched with too much force. That is not a reason to refuse an examination your child's doctor needs, nor to be frightened of one already done. It is the reason one careful examination is followed by imaging, rather than by another examination on every ward round.
Per the PDQ summary, in the Children's Oncology Group system a rupture of the tumour capsule before surgery, or a spill during surgery, places the child in stage III, and stage III treatment includes abdominal radiation and a third chemotherapy drug. The same logic rules out taking tissue first: a biopsy before removal is itself a stage III criterion, so for a tumour the surgeon can take out whole, it is not done.
What replaces the hands is imaging. Bloods and urinalysis come first, then an abdominal ultrasound, often before a definitive CT or MRI of the abdomen and pelvis, and a CT of the chest because about 15 to 20 percent of patients have metastases at presentation. About 4 percent of children presenting with Wilms tumour have an acquired form of von Willebrand disease, a clotting problem with real bleeding risk, which is why clotting is checked before the operation.
The staging that decides what treatment your child gets
Stage describes where tumour was found and whether all of it came out, and it is settled by the surgeon and the pathologist together, not by the first scan. These are the Children's Oncology Group stages as the PDQ summary defines them, with the share of patients in each.
Stage I, about 43 percent: confined to the kidney and completely removed, capsule intact, not ruptured or biopsied before removal, nodes negative. Stage II, about 20 percent: extends beyond the kidney but completely removed with clear margins and negative nodes. Stage III, about 21 percent: tumour remains in the abdomen, which covers involved abdominal or pelvic nodes, peritoneal deposits, tumour at the margins, a tumour that could not be fully removed, rupture before surgery or spill during it, a biopsy before removal, or removal in more than one piece. Stage IV, about 11 percent: spread through the bloodstream to lung, liver, bone or brain, or to nodes outside the abdomen and pelvis. Stage V, about 5 percent: both kidneys at diagnosis.
Treatment follows from that. In North America the kidney usually comes out first, a nephrectomy with lymph node sampling, with chemotherapy after; in Europe chemotherapy is usually given first. For favourable histology, the PDQ summary lists surgery with lymph node biopsy only, and no chemotherapy afterwards, for one narrow group: stage I disease in a child younger than 24 months with a tumour weighing less than 550 g. Otherwise stage I and stage II favourable histology get nephrectomy with lymph node sampling followed by regimen EE-4A, vincristine and dactinomycin, with no radiation, unless the tumour shows loss of heterozygosity at both 1p and 16q, which moves it to DD-4A. Stage III adds abdominal radiation and moves to regimen DD-4A, which is vincristine, dactinomycin and doxorubicin. Stage IV starts with nephrectomy, lymph node sampling, abdominal radiation and regimen DD-4A. It is augmented to regimen M, the DD-4A drugs plus four cycles of cyclophosphamide and etoposide, when the lung nodules have not cleared after six weeks of chemotherapy or there is loss of heterozygosity at 1p and 16q. Stage III with loss of heterozygosity at both 1p and 16q also moves to regimen M.
Per the same summary, the five-year relative survival rate for children younger than 20 years with Wilms tumour is 93 percent. That describes a population rather than a promise, and it is why the team is so careful about the capsule and the nodes.
Which children are already being watched for this?
Some families meet Wilms tumour on a scheduled ultrasound, because the child was already known to be at risk. Per the PDQ summary, an underlying germline predisposition is present in 10 to 15 percent of cases, and 5 to 10 percent of children with Wilms tumour have tumours in both kidneys or in more than one site.
The named conditions carry different risks. In WAGR syndrome the risk is about 50 percent. In Denys-Drash syndrome it is about 90 percent, with both kidneys involved in about 20 percent. In Beckwith-Wiedemann syndrome it depends on the molecular subtype: about 22 to 29 percent for ICR1 gain of methylation, a lower 7 to 17 percent for paternal uniparental disomy, and minimal for CDKN1C variants, where the summary says there are no data to support routine screening. In isolated hemihypertrophy, where one side of the body grows larger than the other, the risk is about 3 to 4 percent.
Each surveillance limit belongs to the recommendation it governs. Children at increased risk are usually screened with ultrasonography every 3 months until they reach at least age 8 years. In Beckwith-Wiedemann syndrome, Wilms screening usually continues until age 8 years, and for the ICR1 gain of methylation and uniparental disomy subtypes the summary gives abdominal ultrasonography every 3 months until age 8 to 10 years. In isolated hemihypertrophy, abdominal ultrasonography with a serum AFP blood test is suggested until age 4 years, and children with isolated hemihypertrophy and negative molecular testing may not need surveillance at all.
If nobody has raised genetics with you, ask: it matters for the other kidney and for a brother or sister.
What it takes to hold a case like this in one place
In one week a family can collect an ultrasound report, a CT report, an operation note, a pathology report and a chemotherapy schedule, each from a different team and in a different format. Keeping them straight is not clerical work. It is the diagnosis.
Healz puts all of it in one chat instead of ten apps, and what makes that worth doing is what sits inside the chat. Frontier AI works the case, so the question you ask at two in the morning meets the strongest AI available. Healz is equipped with root-cause technology, so it cross-references the case against 1M+ rare cases and drills past the first label: on a child's renal mass the mimics get named instead of assumed away, and what the thing arose from stays an open question until the tissue answers it. Healz has memory that keeps every report you upload and connects them over time, so a surveillance ultrasound in March is read against the one from December instead of on its own. Ask it what the stage changes, and you are asking something that already holds the whole record, cancer pathology included, in full context. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Is a kidney mass in a child always cancer?
No, and not every childhood kidney tumour is Wilms tumour either. The NCI PDQ health professional summary covers clear cell sarcoma of the kidney and renal cell carcinoma as separate childhood kidney tumours with their own treatment. Imaging narrows the possibilities, and the pathology after surgery settles them.
- How do doctors tell Wilms tumour from neuroblastoma?
By origin, age and behaviour. Wilms tumour arises inside the kidney and shows a claw of normal kidney tissue around it. Neuroblastoma arises in sympathetic nerve tissue, commonly the adrenal gland, encases vessels, can cross the midline, and calcifies on CT in 80 to 90 percent of cases against about 10 percent in Wilms tumour, a difference MRI picks up less reliably, per a radiological review in Cancer Imaging.
- Does Wilms tumour show up in a urine test?
Not as a marker. The urinary catecholamine metabolites VMA and HVA belong to the neuroblastoma workup, and the NCI PDQ health professional summary on neuroblastoma allows a diagnosis to rest on bone marrow involvement plus raised levels of them. In Wilms tumour, urinalysis is done for other reasons.
- Why is a biopsy not done before the operation?
Because in the Children's Oncology Group system a biopsy before removal is itself a stage III criterion, per the NCI PDQ health professional summary. For a tumour that can be removed whole, taking tissue first would move the child into a stage treated with abdominal radiation and an extra drug.
In a small child, the origin of a kidney mass decides nearly everything that follows, and Healz was built so that origin never gets lost between appointments.
Written by Healz Team · Filed under Health Insights